Clinical Trials

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Leukemia, Leukemia, Mast-Cell, Leukemia, Myeloid, Mastocytosis, Myeloproliferative Disorders, Neoplasms, Neoplasms by Site, Neoplasms, Connective Tissue, Skin Diseases, Soft Tissue Neoplasms, Urticaria Pigmentosa, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Mastocytosis, Systemic

NCT03580655 2026-04-24

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

107 enrolled 30 charts 1 FDA

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT06748001 2026-02-09

Avapritinib Rollover Study

Phase 4 Recruiting

60 enrolled

Phase 2 Active not recruiting

Mastocytosis, Systemic

NCT03731260 2025-09-23

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

251 enrolled

Mastocytosis, Systemic

NCT05609942 2025-04-10

AZURE

Phase 1 Terminated

9 enrolled

Leukemia, Mast-Cell, Mastocytosis, Systemic, Myelodysplastic-Myeloproliferative Diseases

NCT04655118 2024-05-10

Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

Phase 2 Unknown

121 enrolled

CNSDermatologicGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmSarcomaThoracic

Mastocytosis, Systemic, Primary Myelofibrosis

NCT02571036 2023-12-13

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Phase 1 Completed

282 enrolled

Mast Cell Activation Disorders, Carcinoma, Non-Small-Cell Lung, Glioma, Leukemia, Mast-Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Penile Neoplasms, Sarcoma, Mastocytosis, Systemic, Gastrointestinal Stromal Tumors, Renal Insufficiency

NCT04333108 2023-05-06

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

Phase 3 Unknown

140 enrolled

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

NCT02561988 2023-03-17

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Phase 1 Completed

86 enrolled 1 FDA

Leukemia, Mast-Cell, Recurrence, Mastocytosis, Systemic

NCT03214666 2022-11-10

GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies

Phase 1/2 Terminated

12 enrolled 20 charts

Leukemia, Mast-Cell, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

NCT00109707 2021-06-29

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Phase 1/2 Completed

507 enrolled 16 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hypereosinophilic Syndrome, Mastocytosis, Systemic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00814073 2019-12-03

AB06006

Phase 3 Completed

135 enrolled

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

NCT02808793 2019-03-13

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002

Phase 1 Completed

25 enrolled

Mastocytosis, Mastocytosis, Systemic

NCT00782067 2018-11-15

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

116 enrolled 16 charts

Aggression, Leukemia, Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT00171912 2017-02-23

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

MyeloidOther hematologic neoplasmSarcomaThoracic

38 enrolled

Lung Neoplasms, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Dermatofibrosarcoma, Mastocytosis, Systemic, Leukemia, Myelomonocytic, Juvenile

NCT02478957 2016-09-29

Treatment of Indolent Systemic Mastocytosis With PA101

41 enrolled